Stem Cell Therapeutics issued third U.S. patent

By Elaine Rigoli

Tampa, Fla., May 23 - Stem Cell Therapeutics Corp. said Tuesday that the U.S. Patent and Trademark Office has granted U.S. Patent No. 7,048,934 to the company's wholly owned subsidiary, Stem Cell Therapeutics, Inc.

The patent, entitled "Combined Regulation of Neural Cell Production," protects methods of treating patients suffering from a variety of central nervous system disorders, including stroke, brain injury, Alzheimer's disease, multiple sclerosis, Huntington's disease and others.

The combined regulation method of neural-cell production taught in the patent has the potential to be a key technology, required for the successful development of stem cell-based approaches for the treatment of many central nervous system diseases, the company said in a news release.

"I am greatly encouraged by the issuance of this patent, as it claims the concept of a combined approach to successful regeneration of brain tissue. The need to both increase the number of neural stem cells and induce their differentiation to appropriate cell types is likely to be a key step in a variety of stem cell based approaches to the treatment of neurological disorders," president and chief executive officer Joseph Tucker said in the release.

Calgary, Alta.-based Stem Cell Therapeutics is a biotechnology company focused on the development of its technology platform to selectively induce a patient's own stem cells to proliferate in the brain.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.